EMA
European Medicines Agency Adopts Positive Opinion for KEYTRUDA®(pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy
Merck & Co.
PR-M08-18-NI-009Aug 02, 2018
Authorization Application
AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
AbbVie
PR-M05-18-NI-016May 04, 2018